Day: May 4, 2021

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in two upcoming virtual healthcare investor conferences. Presentation Details: Event: BofA Securities 2021 Virtual Health Care Conference Format: Fireside Chat Date: Tuesday, May 11, 2021 Time: 8:45 AM ETEvent: UBS Global Healthcare Virtual Conference Format: Corporate Presentation Date: Tuesday, May 25, 2021 Time: 2:00 PM ET Live webcasts from the BofA and UBS presentations and accompanying presentation materials will be accessible through the Investors...

Updates and increases financial outlook for 2021 Operating highlights:     Three months ended    March 31(in millions of US$, except EPS)   2021       2020                   Revenues $ 774.9     $ 630.6  Adjusted EBITDA (note 1)   92.1       54.5  Adjusted EPS (note 2)   1.04       0.54                   GAAP operating earnings   40.0       18.5  GAAP diluted EPS   0.11       0.11  TORONTO, May 04, 2021 (GLOBE NEWSWIRE) — Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers” or the “Company”) today announced operating and financial results for the quarter ended March 31, 2021. All amounts are in US dollars. For the quarter ended March 31, 2021, revenues were $774.9 million, up 23% (18% in local currency) relative to the same quarter in the prior year, adjusted EBITDA (note 1) was...

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Tuesday, May 11, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2021 and review recent business highlights. A live webcast will be available under “Events and Presentations” in the Investors section of the company’s website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 7598753. A replay of the webcast will be archived on the Imara website following the presentation. About...

Reports Record First Quarter Revenue and Profit; Raises Full-Year Guidance FREMONT, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Corsair Gaming, Inc. (NASDAQ:CRSR) (“Corsair”), a leading global provider and innovator of high-performance gear for gamers and content creators, today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 HighlightsNet revenue was $529.4 million, an increase of 71.6% year-over-year. Gamer and creator peripherals segment net revenue was $175.9 million, an increase of 131.9% year-over-year. Gaming components and systems segment net revenue was $353.5 million, an increase of 51.9% year-over-year. Gross profit was $160.3 million, an increase of 103.9% year-over-year, with gross margin of 30.3%, an improvement of 480 basis points year-over-year. Gamer and creator peripherals...

First Quarter Revenues Totaled $529 Million, An Increase Compared with Both the Sequential and Prior Year Quarters Q1 GAAP Operating Income Of $25 Million And GAAP Diluted Earnings Per Share Of $0.02 Q1 Adjusted Earnings Per Share Of $0.15 Adjusted Q1 EBITDA Totaled $66 Million; Exceeding Previous Guidance Range and Prior-Year Performance Completed Successful Debt Refinancing in Quarter; Transaction Provides Interest Savings, Extends Maturities and Strengthens Financial Position 2021 Adjusted EBITDA Guidance Increased to Between $295 Million and $310 Million, Versus A Prior Range Of $275 Million To $295 Million; Change Reflects Improving Markets in Each Business SegmentCAMP HILL, Pa., May 04, 2021 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC) today reported first quarter 2021 results. On a U.S. GAAP (“GAAP”)...

Executing on $200 Million Exterran Water Solutions Contract Signed During the QuarterRaising Full Year Adjusted EBITDA Guidance to $150-160 millionCapital Structure Strategy Review Underway to Drive Near-Term and Long-Term Success HOUSTON, May 04, 2021 (GLOBE NEWSWIRE) —  Exterran Corporation (NYSE: EXTN) (“Exterran” or the “Company”) today reported first quarter financial results. Andrew Way, Exterran’s President and Chief Executive Officer commented: “I am proud of our team’s continued strong project execution, and safe and efficient work, throughout the first quarter. As previously announced, our Exterran Water Solutions (EWS) business was awarded a significant contract, worth approximately $200 million, that is accelerating the Company’s transition to a sustainable energy industrial business. We are also encouraged by the improving...

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that patient dosing was initiated in a Phase 2 trial intended to assess the efficacy and safety of vidutolimod (CMP-001) in combination with nivolumab for the treatment of patients with anti-PD-1 refractory advanced melanoma. Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Checkmate previously announced initiation of dosing in patients in an additional trial which is evaluating the efficacy and safety of vidutolimod in combination...

CHICAGO, May 04, 2021 (GLOBE NEWSWIRE) — R1 RCM Inc (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended March 31, 2021. First Quarter 2021 Results:Revenue of $342.6 million, up $22.1 million or 6.9% compared to the same period last year   GAAP net income of $25.8 million, up $7.6 million or 41.8% compared to the same period last year   Adjusted EBITDA of $80.4 million, up $18.8 million or 30.5% compared to the same period last year“Our first quarter results reflect continued strong execution by the R1 team, as well as dividends from our investments in digitization,” said Joe Flanagan, President and Chief Executive Officer of R1. “I am encouraged by the demand we see for our...

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Last quarter we reinforced our leadership position in the targeted protein degradation space by sharing the discovery and chemical structures of ARV-110 and ARV-471 at the American Association for Cancer Research (AACR) Annual Meeting, the first such disclosure of our clinical-stage PROTAC degraders,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas. “We look forward to further demonstrating the potential of our PROTAC platform to change the lives of patients with few or no therapeutic options.” Business Highlights...

Authorizes Additional $300 Million Share Repurchase NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the first quarter ended March 31, 2021. First Quarter 2021:Net income of $409.2 million; record Normalized Adjusted Net Income1 of $401.6 million Basic earnings per share of $1.91 and diluted earnings per share of $1.89; Normalized Adjusted EPS1 of $2.04 Record total revenues of $1,012.6 million; Trading income, net, of $812.7 million; Adjusted Net Trading Income1 of $728.0 million Adjusted EBITDA1 of $564.7 million; record Adjusted EBITDA Margin1 of 77.6%“Our remarkable...